PDCD1 and hepatocellular carcinoma: Therefore, we may find the possible synergistic effect between antiviral therapy and anti-PD-1 therapy, and recommend that HBV-related HCC patients who are potential candidates for postoperative anti-PD-1 therapy should receive adequate antiviral therapy before curative surgery to bring HBV DNA to a lower level.